IDEXX Laboratories Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDEXX Laboratories stock.
View analyst ratings for IDEXX Laboratories or view top-rated stocks.

Wall Street analysts have given IDEXX Laboratories a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but IDEXX Laboratories wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

IDEXX Laboratories saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,050,000 shares, an increase of 23.2% from the August 15th total of 852,500 shares. Based on an average trading volume of 360,300 shares, the short-interest ratio is presently 2.9 days. Currently, 1.3% of the company's shares are sold short.
View IDEXX Laboratories' Short Interest.

IDEXX Laboratories is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for IDEXX Laboratories.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Friday, July, 30th. The company reported $2.34 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.01 by $0.33. The business had revenue of $826.14 million for the quarter, compared to the consensus estimate of $794.64 million. IDEXX Laboratories had a net margin of 23.89% and a trailing twelve-month return on equity of 115.28%. The firm's revenue was up 29.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.72 EPS.
View IDEXX Laboratories' earnings history.

IDEXX Laboratories' stock was trading at $245.58 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IDXX stock has increased by 172.7% and is now trading at $669.76.
View which stocks have been most impacted by COVID-19.

IDEXX Laboratories announced that its board has approved a share repurchase plan on Wednesday, February 12th 2020, which authorizes the company to buyback 5,000,000 shares, according to EventVestor. This buyback authorization authorizes the company to buy shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's board believes its shares are undervalued.

IDEXX Laboratories updated its FY 2021 earnings guidance on Friday, August, 6th. The company provided EPS guidance of $8.200-$8.360 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.100. The company issued revenue guidance of $3.17 billion-$3.21 billion, compared to the consensus revenue estimate of $3.14 billion.

5 brokers have issued 12-month price targets for IDEXX Laboratories' stock. Their forecasts range from $570.00 to $770.00. On average, they anticipate IDEXX Laboratories' stock price to reach $675.00 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price.
View analysts' price targets for IDEXX Laboratories or view top-rated stocks among Wall Street analysts.

40 employees have rated IDEXX Laboratories CEO Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among IDEXX Laboratories' employees.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), STERIS (STE), Insulet (PODD), Hologic (HOLX), Teleflex (TFX) and Abiomed (ABMD).
View all of IDXX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Square (SQ), The Walt Disney (DIS) and Shopify (SHOP).

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.66%), BlackRock Inc. (9.73%), State Street Corp (4.27%), Bamco Inc. NY (3.17%), Geode Capital Management LLC (2.01%) and Blair William & Co. IL (1.59%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Bamco Inc. NY, Marshall Wace North America L.P., Alliancebernstein L.P., JPMorgan Chase & Co., Nuveen Asset Management LLC, Vanguard Group Inc., and Westfield Capital Management Co. LP. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson, and Sophie V Vandebroek.
View insider buying and selling activity for IDEXX Laboratories or view top insider-selling stocks.

IDXX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Amundi, State Street Corp, Capital International Investors, Bank of New York Mellon Corp, Neuberger Berman Group LLC, Franklin Resources Inc., and Geode Capital Management LLC.
View insider buying and selling activity for IDEXX Laboratories or or view top insider-buying stocks.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDXX stock can currently be purchased for approximately $669.76.

IDEXX Laboratories has a market capitalization of $56.98 billion and generates $2.71 billion in revenue each year. The company earns $581.78 million in net income (profit) each year or $6.71 on an earnings per share basis.

IDEXX Laboratories employs 9,300 workers across the globe.

IDEXX Laboratories was founded in 1983.

The official website for IDEXX Laboratories is www.idexx.com.

IDEXX Laboratories is headquartered at ONE IDEXX DRIVE, WESTBROOK ME, 04092.

IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The company can be reached via phone at (207) 556-0300 or via email at [email protected].